Sartorius Stedim Biotech shares fell 1.01% to EUR 198.08 on October 22, 2024, despite UBS raising its price target from EUR 194 to EUR 215 after strong quarterly results. Over the past year, shares have increased by 9.62%, although they remain 41.89% below their 52-week high, presenting a potential buying opportunity for investors.
UBS has increased its price target for Sartorius Stedim Biotech from 194 to 215 euros following the release of third-quarter figures, maintaining a "Neutral" rating. Analyst Matthew Weston attributed the adjustment to generally higher valuations within the biotechnology sector.
UBS has increased its price target for Sartorius Stedim Biotech from 194 to 215 euros, maintaining a "Neutral" rating. Analyst Matthew Weston attributed this adjustment to higher industry valuations following the company's third-quarter results. As of October 22, 2024, Sartorius shares were trading at approximately 199.10 euros, reflecting a slight decline of 0.43%.
UBS has increased its price target for Sartorius Stedim Biotech from 194 to 215 euros following the release of third-quarter figures, maintaining a "Neutral" rating. Analyst Matthew Weston attributed the adjustment to generally higher valuations within the biotechnology sector.
Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.
